Thermo Fisher Scientific has announced a collaboration with OpenAI that could reshape how new medicines are developed. The partnership will initially focus on integrating OpenAI’s advanced language and reasoning models into Thermo Fisher’s clinical research business, PPD, to shorten clinical trial cycles and bring treatments to market faster.
By embedding OpenAI’s technology into its Accelerator Drug Development platform, Thermo Fisher aims to apply AI across every stage of the process, from early development and manufacturing to commercialization. The companies also plan to use AI to identify therapies that are unlikely to succeed, helping pharmaceutical clients redirect resources toward more promising candidates.
According to OpenAI’s Chief Operating Officer Brad Lightcap, the partnership reflects a shared mission to advance science at scale. “Thermo Fisher plays a massive role in advancing science, and together we have an opportunity to accelerate how medicine can reach more people,” Lightcap said. “With OpenAI directly powering Thermo Fisher workflows, frontier AI can help cut through complexity, speed up breakthroughs, and bring real impact to patients’ lives.”
Thermo Fisher employees will also gain access to ChatGPT Enterprise, encouraging greater fluency with AI tools. If successful, this collaboration could mark one of the most meaningful applications of generative AI in clinical research, turning hype into measurable health outcomes.
